Outlook on the TIL Therapies Global Market to 2035: by Target Indication, Key Players and Key Geographical Regions
February 01, 2023 06:33 ET
|
Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts,...
Flow Cytometry in Oncology and Immunology Global Market Report 2022: Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
November 29, 2022 04:03 ET
|
Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry in Oncology and Immunology Market - A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and...
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
Mendus AB: Mendus presenterar positiva kliniska och prekliniska data vid behandling av äggstockscancer på European Society of Gynaecological Oncology 2022
October 17, 2022 02:15 ET
|
Mendus AB
RESULTATEN STÖDJER POTENTIALEN FÖR MENDUS IMMUNTERAPIKANDIDAT DCP-001 FÖR SÅVÄL NY UNDERHÅLLSBEHANDLING SOM AKTIV BEHANDLING I EN BETYDANDE INDIKATION AV SOLIDA TUMÖRER Mendus AB (“Mendus” publ;...
Mendus AB: Mendus to report positive clinical and preclinical data in ovarian cancer at the European Society of Gynaecological Oncology 2022 Congress
October 17, 2022 02:15 ET
|
Mendus AB
RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on...
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
September 22, 2022 18:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
September 12, 2022 07:30 ET
|
Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
September 12, 2022 07:30 ET
|
Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
Doxorubicin Market Revenue to Cross $1,983.40 million by 2028 to Rise at a Stellar CAGR of 6.1% by 2028 | Exclusive Research by The Insight Partners
July 12, 2022 10:54 ET
|
The Insight Partners
New York, July 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Formulation,...